FY2024 EPS Estimates for Organogenesis Holdings Inc. Increased by Cantor Fitzgerald (NASDAQ:ORGO)

Organogenesis Holdings Inc. (NASDAQ:ORGO) – Equities researchers at Cantor Fitzgerald lifted their FY2024 earnings per share (EPS) estimates for shares of Organogenesis in a report issued on Wednesday, October 9th. Cantor Fitzgerald analyst R. Osborn now expects that the company will earn ($0.17) per share for the year, up from their prior forecast of ($0.20). The consensus estimate for Organogenesis’ current full-year earnings is ($0.19) per share.

Separately, Lake Street Capital began coverage on Organogenesis in a research note on Friday, June 28th. They issued a “buy” rating and a $5.00 price objective on the stock.

Organogenesis Stock Up 5.9 %

Shares of Organogenesis stock opened at $3.07 on Friday. The stock has a 50-day moving average price of $2.77 and a 200 day moving average price of $2.76. Organogenesis has a 1 year low of $1.96 and a 1 year high of $4.70. The company has a market cap of $406.99 million, a P/E ratio of -23.62 and a beta of 1.60. The company has a current ratio of 2.73, a quick ratio of 2.42 and a debt-to-equity ratio of 0.22.

Organogenesis (NASDAQ:ORGO) last released its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). Organogenesis had a negative return on equity of 6.03% and a negative net margin of 3.69%. The firm had revenue of $130.23 million during the quarter, compared to analyst estimates of $122.48 million.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its stake in shares of Organogenesis by 15.4% in the second quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company’s stock valued at $87,000 after buying an additional 4,130 shares during the period. Price T Rowe Associates Inc. MD raised its position in Organogenesis by 11.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 50,951 shares of the company’s stock valued at $145,000 after purchasing an additional 5,359 shares during the last quarter. Mackenzie Financial Corp boosted its position in Organogenesis by 46.1% during the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock worth $68,000 after buying an additional 7,678 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Organogenesis by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company’s stock worth $755,000 after purchasing an additional 9,054 shares during the last quarter. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Organogenesis in the 2nd quarter valued at about $38,000. 49.57% of the stock is currently owned by institutional investors and hedge funds.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.